Dr. Daniel Costa, MD, PhD
Claim this profileBeth Israel Deaconess Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
21 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
Stage III
2Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials Daniel Costa, MD, PhD is currently running
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
Selpercatinib
for Non-Small Cell Lung Cancer
This trial is testing if the drug selpercatinib can safely and effectively prevent lung cancer from returning in patients who have had treatment. It focuses on people with early-stage lung cancer. The drug works by blocking proteins that help cancer cells grow.
Recruiting1 award Phase 38 criteria
More about Daniel Costa, MD, PhD
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Daniel Costa, MD, PhD has experience with
- Osimertinib
- Carboplatin
- APL-101
- Cisplatin
- TAK-788
- Pemetrexed
Breakdown of trials Daniel Costa, MD, PhD has run
Lung Cancer
Non-Small Cell Lung Cancer
Epidermal Growth Factor Receptor Mutations
MET Amplification
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Costa, MD, PhD specialize in?
Daniel Costa, MD, PhD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Daniel Costa, MD, PhD currently recruiting for clinical trials?
Yes, Daniel Costa, MD, PhD is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Daniel Costa, MD, PhD has studied deeply?
Yes, Daniel Costa, MD, PhD has studied treatments such as Osimertinib, Carboplatin, APL-101.
What is the best way to schedule an appointment with Daniel Costa, MD, PhD?
Apply for one of the trials that Daniel Costa, MD, PhD is conducting.
What is the office address of Daniel Costa, MD, PhD?
The office of Daniel Costa, MD, PhD is located at: Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States. This is the address for their practice at the Beth Israel Deaconess Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.